Topic starter
19/08/2026 3:40 pm
TL;DR: Medical device manufacturers are being pushed to treat SBOMs as a design-time security and compliance control, not a documentation afterthought, because about 96% of device software now depends on open source components and FDA requirements are tightening, according to Kusari. That shift makes software transparency, vulnerability correlation, and lifecycle accountability central to patient safety and regulatory readiness.
Editorial analysis by NHI Mgmt Group, based on content published by Kusari: “Securing Medical Devices: Cyber Threats, SBOMs, and FDA Premarket Readiness”.
Key questions
Q: How should medical device teams make SBOMs operational instead of treating them as paperwork?
A: SBOMs become operational when they are generated automatically, machine-readable, and continuously matched to vulnerability and exploitability data.
Q: Why do SBOMs matter so much for regulated medical devices?
A: They provide the evidence base for understanding what software is inside a device, which components are unsupported, and where known vulnerabilities may affect patient safety or product availability.
Q: What breaks when SBOMs are treated as static compliance documents?
A: When SBOMs are static, teams lose the operational value they were meant to provide.
Practitioner guidance
- Build SBOM generation into the release pipeline Generate machine-readable SBOMs automatically as part of software build and release rather than assembling them manually after the fact.
- Correlate SBOMs with vulnerability and exploitability data Join SBOM records to CVE intelligence, support status, and exploitability context so teams can distinguish exposure from actionable patient risk.
- Track component support and end-of-life dates Maintain a live view of which components are supported, approaching end of life, or already unsupported, and tie that view to release approvals.
Bottom line: SBOMs in medical devices now function as a design-time control because software composition, support status, and vulnerability exposure all affect safety and release decisions.
Explore further
View Full Forum → | NHI Foundation Course → | Our Services → | Read the full analysis →
19/08/2026 4:19 pm
SBOM governance is now a design-time security control, not a documentation exercise. In medtech, the SBOM has become the point where software composition, support status, and regulatory duty converge. That shifts the control from after-the-fact reporting to pre-release decision-making, which is exactly where safety risk should be governed.
A question worth separating out:
Q: Who should own SBOM-based remediation decisions in a medical device programme?
A: Ownership should sit across engineering, security, quality, regulatory, and legal functions because SBOM findings affect product safety, release decisions, disclosure obligations, and post-market support. A single team can assemble the data, but no single team can govern the risk alone.
👉 Read our full editorial: SBOMs are becoming a design-time control for medtech cybersecurity